FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Morris Blajchman

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Rabbits

Anatomy

Concepts & Ideas

Molecular Sequence Data

Geographic Areas

Canada

Co-author Network

Publications

TOP 3
Mark E Brecher; Paul M Ness; Roslyn Yomtovian; Morris A Blajchman; James P AuBuchon
Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future.
Dean A Fergusson; Jason C Ford; Paul Hébert; Debora L Hogan; Brian Hutton; Ashok Kakadekar; Lajos Kovacs; Christian Lachance; Louise LeBel; Shoo Lee; Kuppuchipalayam Ramesh; Tim Ramsay; Nicole Rouvinez-Bouali; Koravangattu Sankaran; Katelyn Balchin; Morris A Blajchman; Robin Ducharme; John A Smyth; Alan Tinmouth; C Robin Walker; Stan Shapiro
Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial.
Morris A Blajchman; Jeffrey L Carson; John W Eikelboom; Simone Glynn; Nancy M Heddle; Jacques Lacroix; Michael S Lauer; Traci Heath Mondoro; Richard Platt; Barbara Tilley; Darrell Triulzi; Andrew J Vickers; Salim Yusuf; Elizabeth Wagner
The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Morris Blajchman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mark E Brecher; Paul M Ness; Roslyn Yomtovian; Morris A Blajchman; James P AuBuchon
Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future.
Transfusion 2013;53(1):221-31.
2012: Dean A Fergusson; Jason C Ford; Paul Hébert; Debora L Hogan; Brian Hutton; Ashok Kakadekar; Lajos Kovacs; Christian Lachance; Louise LeBel; Shoo Lee; Kuppuchipalayam Ramesh; Tim Ramsay; Nicole Rouvinez-Bouali; Koravangattu Sankaran; Katelyn Balchin; Morris A Blajchman; Robin Ducharme; John A Smyth; Alan Tinmouth; C Robin Walker; Stan Shapiro
Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial.
JAMA : the journal of the American Medical Association 2012;308(14):1443-51.
2012: Morris A Blajchman; Jeffrey L Carson; John W Eikelboom; Simone Glynn; Nancy M Heddle; Jacques Lacroix; Michael S Lauer; Traci Heath Mondoro; Richard Platt; Barbara Tilley; Darrell Triulzi; Andrew J Vickers; Salim Yusuf; Elizabeth Wagner
The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.
Transfusion 2012;52(6):1363-78.
2012: Douglas B Cines; Katherine A High; Morris A Blajchman; James B Bussel
Clinical trial opportunities in hemostasis and thrombosis: NHBLI State-of-the-science symposium.
American journal of hematology 2012;87(2):235-8.
2011: Judie Leach Bennett; Margaret Fearon; Morris A Blajchman; Gilles Delage; Dana Devine
Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety.
Transfusion medicine reviews 2011;25(4):267-92.
2011: Jacques Lacroix; John C Marshall; Lauralyn McIntyre; Alan Tinmouth; Alexis F Turgeon; Morris A Blajchman; Jeannie Callum; Deborah Cook; Dean Fergusson; Paul Hébert
The Age of Blood Evaluation (ABLE) randomized controlled trial: study design.
Transfusion medicine reviews 2011;25(3):197-205.
2011: Cassandra D Josephson; Simone A Glynn; Steve H Kleinman; Morris A Blajchman
A multidisciplinary "think tank": the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium.
Transfusion 2011;51(4):828-41.
2011: Walter H Dzik; Dean Fergusson; Morad Hameed; Blair Henry; Andrew W Kirkpatrick; Teresa Korogyi; Sarvesh Logsetty; Charles MacAdams; Robert C Skeate; Simon Stanworth; Morris A Blajchman; Brian Muirhead
Clinical review: Canadian National Advisory Committee on Blood and Blood Products--Massive transfusion consensus conference 2011: report of the panel.
Critical care (London, England) 2011;15(6):242.
2010: Morris A Blajchman; Simone A Glynn; Cassandra D Josephson; Steve H Kleinman
Clinical trial opportunities in Transfusion Medicine: proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium.
Transfusion medicine reviews 2010;24(4):259-85.
2010: Melca M O Barros; Morris A Blajchman; José O Bordin
Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment.
Transfusion medicine reviews 2010;24(3):195-210.
2010: Eleftherios C Vamvakas; Morris A Blajchman
Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality.
Transfusion medicine reviews 2010;24(2):77-124.
2010: Ching Y Voss; Terry J Fry; Max J Coppes; Morris A Blajchman
Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis.
Transfusion medicine reviews 2010;24(1):22-32.
2009: HARVEY KLEIN; Simone A Glynn; Paul M Ness; Morris A Blajchman
Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
Transfusion 2009;49(6):1262-8.
2009: Morris A Blajchman
Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
Transfusion clinique et biologique : journal de la Société française de transfusion sanguine 2009;16(2):70-4.
2009: Eleftherios C Vamvakas; Morris A Blajchman
Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention.
Blood 2009;113(15):3406-17.
2009: Craig D Ainsworth; Mark A Crowther; Darin J Treleaven; Denise Evanovitch; Kathryn E Webert; Morris A Blajchman
Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review.
Transfusion medicine reviews 2009;23(2):155-9.
2009: Dean Fergusson; Brian Hutton; Debora L Hogan; Louise LeBel; Morris A Blajchman; Jason C Ford; Paul Hebert; Ashok Kakadekar; Lajos Kovacs; Shoo Lee; Koravangattu Sankaran; Stan Shapiro; John A Smyth; Kuppuchipalayam Ramesh; Nicole Rouvinez Bouali; Alan Tinmouth; Robin Walker
The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design.
Transfusion medicine reviews 2009;23(1):55-61.
2008: Bryan J Clarke; Morris A Blajchman
Human FVII(K62E) does not exhibit enhanced binding to tissue factor.
Journal of thrombosis and haemostasis : JTH 2008;6(7):1229.
2008: Dean A Fergusson; Paul C Hébert; C David Mazer; Stephen Fremes; Charles MacAdams; John M Murkin; Kevin Teoh; Peter C Duke; Ramiro Arellano; Morris A Blajchman; Jean S Bussières; Dany Côté; Jacek Karski; Raymond Martineau; James A Robblee; Marc Rodger; George Wells; Jennifer Clinch; Roanda Pretorius
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
The New England journal of medicine 2008;358(22):2319-31.
2008: David A Clark; Reginald M Gorczynski; Morris A Blajchman
Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
Transfusion 2008;48(5):814-21.
2008: Wafaa Y Bassuni; Morris A Blajchman; May A Al-Moshary
Why implement universal leukoreduction?
Hematology/oncology and stem cell therapy 2008;1(2):106-23.
2008: David A Clark; Karrie Wong; Daljeet Banwatt; Ziqhi Chen; Jian Liu; Lydia Lee; Reginald M Gorczynski; Morris A Blajchman
CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG.
Journal of assisted reproduction and genetics 2008;25(2-3):67-72.
2008: Kathryn E Webert; Christine M Cserti; Judith Hannon; Yulia Lin; Katerina Pavenski; Jacob M Pendergrast; Morris A Blajchman
Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.
Transfusion medicine reviews 2008;22(1):1-34.
2008: Kathryn E Webert; Richard J Cook; Stephen Couban; Julie Carruthers; Ker-Ai Lee; Morris A Blajchman; Jeffrey H Lipton; Joseph Brandwein; Nancy M Heddle
A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.
Transfusion 2008;48(1):81-91.
2007: Eleftherios C Vamvakas; Morris A Blajchman
Transfusion-related immunomodulation (TRIM): an update.
Blood reviews 2007;21(6):327-48.
2007: Donald M Arnold; Morris A Blajchman; Julie DiTomasso; Myron Kulczycki; Paul K Keith
Passive transfer of peanut hypersensitivity by fresh frozen plasma.
Archives of internal medicine 2007;167(8):853-4.
2006: Valia Lestou; Nancy Ondrusek; Morris A Blajchman
Research ethics boards: the protection of human subjects.
PLoS medicine 2006;3(10):e472; author reply e471.
2006: Morris A Blajchman; Eleftherios C Vamvakas
The continuing risk of transfusion-transmitted infections.
The New England journal of medicine 2006;355(13):1303-5.
2006: Haresh Kirpalani; Robin K Whyte; Chad Andersen; Elizabeth V Asztalos; Nancy M Heddle; Morris A Blajchman; Abraham Peliowski; Angel Rios; Meena LaCorte; Robert Connelly; Keith J Barrington; Robin S Roberts
The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants.
The Journal of pediatrics 2006;149(3):301-307.
2006: Morris A Blajchman
The clinical benefits of the leukoreduction of blood products.
The Journal of trauma 2006;60(6 Suppl):S83-90.
2006: Donald M Arnold; Dean A Fergusson; Anthony K C Chan; Richard J Cook; Graeme A Fraser; Wendy Lim; Morris A Blajchman; Deborah J Cook
Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin.
Anesthesia and analgesia 2006;102(3):731-7.
2006: Donald M Arnold; Nancy M Heddle; Myron Kulczycky; Julie Carruthers; Christopher Sigouin; Morris A Blajchman
In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers.
Transfusion 2006;46(2):257-64.
2006: Kathryn E Webert; Morris A Blajchman
Randomized trials in patients with blunt and penetrating trauma.
The Journal of trauma 2006;60(1):242-3; author reply 243-4.
2005: Kathryn E Webert; Morris A Blajchman
Transfusion-related acute lung injury.
Current opinion in hematology 2005;12(6):480-7.
2005: Morris A Blajchman; Erik A M Beckers; Ebbe Dickmeiss; Lilly Lin; Gillian Moore; Ludo Muylle
Bacterial detection of platelets: current problems and possible resolutions.
Transfusion medicine reviews 2005;19(4):259-72.
2005: Morris A Blajchman
Landmark studies that have changed the practice of transfusion medicine.
Transfusion 2005;45(9):1523-30.
2005: Nancy M Heddle; Rebecca Barty; Christopher Sigouin; D M Boye; E J Nelson; Morris A Blajchman; John G Kelton
In vitro evaluation of prestorage pooled leukoreduced whole blood-derived platelets stored for up to 7 days.
Transfusion 2005;45(6):904-10.
2005: Nancy M Heddle; Richard J Cook; Morris A Blajchman; Rebecca Barty; Christopher Sigouin; D M Boye; E J Nelson; John G Kelton
Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
Transfusion 2005;45(6):896-903.
2005: V Williamson; A Pyke; Sampath Sridhara; R F Kelley; Morris A Blajchman; Bryan J Clarke
Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII.
Journal of thrombosis and haemostasis : JTH 2005;3(6):1250-6.
2005: Paul C Hébert; Ian H Chin-Yee; Dean Fergusson; Morris A Blajchman; Raymond Martineau; Jennifer Clinch; Bernhard Olberg
A pilot trial evaluating the clinical effects of prolonged storage of red cells.
Anesthesia and analgesia 2005;100(5):1433-8, table of contents.
2005: Jean-Pierre Allain; Celso Bianco; Morris A Blajchman; Mark E Brecher; Michael Busch; David Leiby; Lily Lin; Susan L Stramer
Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
Transfusion medicine reviews 2005;19(2):110-26.
2005: Mindy Goldman; Kathryn E Webert; Donald M Arnold; John Freedman; Judith Hannon; Morris A Blajchman
Proceedings of a consensus conference: towards an understanding of TRALI.
Transfusion medicine reviews 2005;19(1):2-31.
2005: Paul C Hébert; Dean A Fergusson; David Stather; Lauralyn McIntyre; Claudio Martin; Steve Doucette; Morris A Blajchman; Ian D Graham
Revisiting transfusion practices in critically ill patients.
Critical care medicine 2005;33(1):7-12; discussion 232-2.
2004: Mark H Yazer; Morris A Blajchman; Julie DiTomasso; Gregory Denomme
ABO sequence analysis in a family with weak expression of blood group B.
Transfusion 2004;44(9):1394-5.
2004: Donald M Arnold; Giuseppe Molinaro; Theodore E Warkentin; Julie DiTomasso; Kathryn E Webert; Ian Davis; Lawrence Lesiuk; Geoffrey Dunn; Nancy M Heddle; Albert Adam; Morris A Blajchman
Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage.
Transfusion 2004;44(9):1361-6.
2004: Morris A Blajchman
The top ten list of randomized controlled trials in transfusion medicine.
Vox sanguinis 2004;87 Suppl 2():193-6.
2004: Morris A Blajchman
Bacterial contamination of cellular blood components: risks, sources and control.
Vox sanguinis 2004;87 Suppl1():98-103.
2004: Mark W C Hatton; Suzanne M R Southward; Kimberly J Legault; Bonnie L Ross; Bryan J Clarke; Laszlo Bajzar; Morris A Blajchman; Gurmit Singh; Mary Richardson
Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
The Journal of laboratory and clinical medicine 2004;143(4):241-54.
2004: Morris A Blajchman; Mindy Goldman; Kathryn E Webert; Eleftherios C Vamvakas; Judith Hannon; Gilles Delage
Proceedings of a consensus conference: the screening of blood donors for variant CJD.
Transfusion medicine reviews 2004;18(2):73-92.
2004: Morris A Blajchman; Mindy Goldman; Federico Baeza
Improving the bacteriological safety of platelet transfusions.
Transfusion medicine reviews 2004;18(1):11-24.
2003: Kathryn E Webert; Morris A Blajchman
Transfusion-related acute lung injury.
Transfusion medicine reviews 2003;17(4):252-62.
2003: Morris A Blajchman
Substitutes and alternatives to platelet transfusions in thrombocytopenic patients.
Journal of thrombosis and haemostasis : JTH 2003;1(7):1637-41.
2003: Dean Fergusson; Paul C Hébert; Shoo K Lee; C Robin Walker; Keith J Barrington; Lawrence Joseph; Morris A Blajchman; Stan Shapiro
Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants.
JAMA : the journal of the American Medical Association 2003;289(15):1950-6.
2003: Paul C Hébert; Dean Fergusson; Morris A Blajchman; George A Wells; Andrew Kmetic; Douglas Coyle; Nancy M Heddle; Marc Germain; Mindy Goldman; Baldwin Toye; Irwin Schweitzer; Carl vanWalraven; Dana Devine; Graham D Sher
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions.
JAMA : the journal of the American Medical Association 2003;289(15):1941-9.
2003: Jill R Storry; Laima Sausais; Kim Hue-Roye; Flora Mudiwa; Zennie Ferrer; Morris A Blajchman; Douglas M Lublin; Bei-Wen Ma; Juan Miquel; Flavio Nervi; Jaime Pereira; Marion E Reid
GUTI: a new antigen in the Cromer blood group system.
Transfusion 2003;43(3):340-4.
2003: Mikael Tranholm; Rasmus Rojkjaer; Charles Pyke; Annemarie T Kristensen; Birgitte Klitgaard; Karsten Lollike; Morris A Blajchman
Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
Thrombosis research 2003;109(4):217-23.
2003: Christopher D Hillyer; Cassandra D Josephson; Morris A Blajchman; Jaroslav G Vostal; Jay S Epstein; Jesse Goodman
Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():575-89.
2003: Kumanan Wilson; Laura MacDougall; Brigitte Pinard; Mohammad A Amin; Dean Fergusson; Ian Graham; Morris A Blajchman; John Freedman; Doug Angus; Paul C Hébert
How should Canada fund the blood system? An evaluation of the chargeback proposal.
Hospital quarterly 2003;6(3):47-4.
2002: Bryan J Clarke; Sampath Sridhara; Zofia Woskowska; Morris A Blajchman
Consumption of plasma factor VII in a rabbit model of non-overt disseminated intravascular coagulation.
Thrombosis research 2002;108(5-6):329-34.
2002: Jack Corman; Morris A Blajchman; Allan Knight
Placebo tribulations.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002;167(5):455-6; author reply 456-7.
2002: Morris A Blajchman
Immunomodulation and blood transfusion.
American journal of therapeutics 2002;9(5):389-95.
2002: Nancy M Heddle; Morris A Blajchman; Ralph M Meyer; Jeff H Lipton; Irwin R Walker; Graham D Sher; Lorrie A Constantini; Bruce Patterson; Robin S Roberts; Kevin E Thorpe; Mark N Levine
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.
Transfusion 2002;42(5):556-66.
2002: Mark W C Hatton; Suzanne M R Southward; Bonnie L Ross; Kimberly Legault; Lindsay Marien; Darren Korbie; Mary Richardson; Gurmit Singh; Bryan J Clarke; Morris A Blajchman
Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors.
The Journal of laboratory and clinical medicine 2002;139(5):316-23.
2002: Morris A Blajchman
Incidence and significance of the bacterial contamination of blood components.
Developments in biologicals 2002;108():59-67.
2001: Morris A Blajchman; Mindy Goldman
Bacterial contamination of platelet concentrates: incidence, significance, and prevention.
Seminars in hematology 2001;38(4 Suppl 11):20-6.
2001: DH Lee; Morris A Blajchman
Novel treatment modalities: new platelet preparations and substitutes.
British journal of haematology 2001;114(3):496-505.
2001: Mark W C Hatton; Morris A Blajchman; Sampath Sridhara; Suzanne M R Southward; Bonnie Ross; M Kulzcycky; Bryan J Clarke
Metabolism of rabbit plasma-derived factor VII in relation to prothrombin in rabbits.
American journal of physiology. Endocrinology and metabolism 2001;281(3):E507-15.
2001: Morris A Blajchman
Bacterial contamination of blood products.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2001;24(3):245.
2001: Morris A Blajchman
Novel platelet products, substitutes and alternatives.
Transfusion clinique et biologique : journal de la Société française de transfusion sanguine 2001;8(3):267-71.
2001: Morris A Blajchman; P C Hébert
Red blood cell transfusion strategies.
Transfusion clinique et biologique : journal de la Société française de transfusion sanguine 2001;8(3):207-10.
2001: Paul C Hébert; Morris A Blajchman; Deborah J Cook; Elizabeth Yetisir; George Wells; John Marshall; Irwin Schweitzer
Do blood transfusions improve outcomes related to mechanical ventilation?
Chest 2001;119(6):1850-7.
2001: Morris A Blajchman; Sunny Dzik; Eleftherios C Vamvakas; J Sweeney; E L Snyder
Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference.
Transfusion medicine reviews 2001;15(2):108-35.
2001: Paul C Hébert; Elizabeth Yetisir; Claudio Martin; Morris A Blajchman; George Wells; John Marshall; M Tweeddale; Giuseppe Pagliarello; Irwin Schweitzer
Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?
Critical care medicine 2001;29(2):227-34.
2001: T C Brutzki; Myron Kulczycky; L Bardossy; Bryan J Clarke; Morris A Blajchman
Rapid in vivo induction of leukocyte tissue factor mRNA and protein synthesis following low dose endotoxin administration to rabbits.
The hematology journal : the official journal of the European Haematology Association / EHA 2001;2(3):188-95.
2001: Morris A Blajchman; Mindy Goldman; J J Freedman; G D Sher
Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction.
Transfusion medicine reviews 2001;15(1):1-20.
2000: D H Lee; L Bardossy; N Peterson; Morris A Blajchman
o-raffinose cross-linked hemoglobin improves the hemostatic defect associated with anemia and thrombocytopenia in rabbits.
Blood 2000;96(10):3630-6.
2000: B J Leonard; Bryan J Clarke; Sampath Sridhara; R Kelley; Frederick A Ofosu; Morris A Blajchman
Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human factor VII.
The Journal of biological chemistry 2000;275(45):34894-900.
2000: H Ni; Morris A Blajchman; Vettai S Ananthanarayanan; IJ Smith; William P Sheffield
Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin.
Thrombosis research 2000;99(4):407-15.
2000: S M Ruiz; Sampath Sridhara; Morris A Blajchman; Bryan J Clarke
Expression and purification of recombinant rabbit factor VII.
Thrombosis research 2000;98(2):203-11.
2000: DH Lee; Morris A Blajchman
Platelet substitutes and novel platelet products.
Expert opinion on investigational drugs 2000;9(3):457-69.
2000: D H Lee; Irwin R Walker; Jerome M Teitel; Man-Chiu Poon; B Ritchie; J Akabutu; Gary D Sinclair; Mohan Pai; J W Wu; S Reddy; C Carter; G Growe; David Lillicrap; M Lam; Morris A Blajchman
Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A.
Thrombosis and haemostasis 2000;83(3):387-91.
2000: Morris A Blajchman
Platelet substitutes.
Vox sanguinis 2000;78 Suppl 2():183-6.
2000: Morris A Blajchman
Reducing the risk of bacterial contamination of cellular blood components.
Developments in biologicals 2000;102():183-93.
2000: CP Engelfriet; Henk W Reesink; Morris A Blajchman; Ludo Muylle; J Kjeldsen-Kragh; Riitta Kekomäki; R Yomtovian; P Höcker; G Stiegler; HARVEY KLEIN; K Soldan; J Barbara; A Slopecki; A Robinson; H Seyfried
Bacterial contamination of blood components.
Vox sanguinis 2000;78(1):59-67.
1999: Mark W C Hatton; Bonnie Ross; L Bardossy; Suzanne M R Southward; M DeReske; Mary Richardson; Morris A Blajchman
The procoagulant state of the VX-2 tumor in rabbit lung in vivo--relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor.
Thrombosis and haemostasis 1999;82(6):1694-702.
1999: MJ Wells; William P Sheffield; Morris A Blajchman
The clearance of thrombin-antithrombin and related serpin-enzyme complexes from the circulation: role of various hepatocyte receptors.
Thrombosis and haemostasis 1999;81(3):325-37.
1999: Paul C Hébert; George Wells; Morris A Blajchman; John Marshall; Claudio Martin; Giuseppe Pagliarello; M Tweeddale; Irwin Schweitzer; Elizabeth Yetisir
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.
The New England journal of medicine 1999;340(6):409-17.
1999: Mark W C Hatton; Bonnie Ross; Suzanne M R Southward; M DeReske; H Hoogendoorn; Morris A Blajchman; Mary Richardson
Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen.
The Journal of laboratory and clinical medicine 1999;133(1):81-7.
1998: MJ Wells; Morris A Blajchman
In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans.
The Journal of biological chemistry 1998;273(36):23440-7.
1998: DH Lee; Morris A Blajchman
Novel platelet products and substitutes.
Transfusion medicine reviews 1998;12(3):175-87.
1998: Paul C Hébert; George Wells; Claudio Martin; M Tweeddale; John Marshall; Morris A Blajchman; Giuseppe Pagliarello; Irwin Schweitzer; L Calder
A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group.
Critical care medicine 1998;26(3):482-7.
1998: D H Lee; J E Paling; Morris A Blajchman
A new tool for communicating transfusion risk information.
Transfusion 1998;38(2):184-8.
1998: Morris A Blajchman
Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms.
Vox sanguinis 1998;74 Suppl 2():315-9.
1998: Morris A Blajchman
Bacterial contamination and proliferation during the storage of cellular blood products.
Vox sanguinis 1998;74 Suppl 2():155-9.
1998: B J Leonard; Q Chen; Morris A Blajchman; Frederick A Ofosu; Sampath Sridhara; D Yang; Bryan J Clarke
Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain.
Blood 1998;91(1):142-8.
1997: Mark W C Hatton; Suzanne M R Southward; Morris A Blajchman; Bonnie Ross; P D Winocour; Mary Richardson
Comparative catabolism of prothrombin and antithrombin in normal and alloxan-diabetic rabbits.
Metabolism: clinical and experimental 1997;46(12):1406-11.
1997: MJ Wells; Mark W C Hatton; Bryan Hewlett; Thomas J Podor; William P Sheffield; Morris A Blajchman
Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes.
The Journal of biological chemistry 1997;272(45):28574-81.
1997: M A Cunningham; Morris A Blajchman; William P Sheffield
Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase.
Thrombosis research 1997;88(2):171-81.
1997: H Margolis-Nunno; L Bardossy; R Robinson; E Ben-Hur; B Horowitz; Morris A Blajchman
Psoralen-mediated photodecontamination of platelet concentrates: inactivation of cell-free and cell-associated forms of human immunodeficiency virus and assessment of platelet function in vivo.
Transfusion 1997;37(9):889-95.
1997: Mark W C Hatton; H Hoogendoorn; Suzanne M R Southward; Bonnie Ross; Morris A Blajchman
Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits.
The American journal of physiology 1997;272(5 Pt 1):E824-31.
1997: Paul C Hébert; George Wells; M Tweeddale; Claudio Martin; John Marshall; B Pham; Morris A Blajchman; Irwin Schweitzer; Giuseppe Pagliarello
Does transfusion practice affect mortality in critically ill patients? Transfusion Requirements in Critical Care (TRICC) Investigators and the Canadian Critical Care Trials Group.
American journal of respiratory and critical care medicine 1997;155(5):1618-23.
1997: Morris A Blajchman; DH Lee
The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes.
Transfusion medicine reviews 1997;11(2):95-105.
1996: F A Fernandez-Rachubinski; J H Weiner; Morris A Blajchman
Regions flanking exon 1 regulate constitutive expression of the human antithrombin gene.
The Journal of biological chemistry 1996;271(46):29502-12.
1996: S Sridhara; S Chaing; Katherine A High; Morris A Blajchman; B J Clarke
Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor.
American journal of hematology 1996;53(2):66-71.
1996: Mark W C Hatton; Suzanne M R Southward; B Ross-Ouellet; M DeReske; Morris A Blajchman; Mary Richardson
An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(9):1147-55.
1996: Frederick A Ofosu; S Craven; L Dewar; N Anvari; M Andrew; Morris A Blajchman
Age-related changes in factor VII proteolysis in vivo.
British journal of haematology 1996;94(2):407-12.
1996: D H Lee; P A Henderson; Morris A Blajchman
Prevalence of factor V Leiden in a Canadian blood donor population.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1996;155(3):285-9.
1996: L Liu; John Freedman; A Hornstein; L Dewar; Morris A Blajchman; Frederick A Ofosu
Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets.
British journal of haematology 1996;92(2):458-65.
1996: H Moraes-Souza; José Orlando Bordin; L Bardossy; Morris A Blajchman
Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultraviolet A (UV-A) light: preliminary results.
Revista da Sociedade Brasileira de Medicina Tropical 1996;29(1):47-9.
1995: Mark W C Hatton; Suzanne M R Southward; S D Serebrin; M Kulczycky; Morris A Blajchman
Catabolism of rabbit prothrombin in rabbits: uptake of prothrombin by the aorta wall before and after a de-endothelializing injury in vivo.
The Journal of laboratory and clinical medicine 1995;126(6):521-9.
1995: William P Sheffield; J E Castillo; Morris A Blajchman
Intracellular events determine the fate of antithrombin Utah.
Blood 1995;86(9):3461-7.
1995: H Moraes-Souza; José Orlando Bordin; L Bardossy; D W MacPherson; Morris A Blajchman
Prevention of transfusion-associated Chagas' disease: efficacy of white cell-reduction filters in removing Trypanosoma cruzi from infected blood.
Transfusion 1995;35(9):723-6.
1995: P Holman; Morris A Blajchman; Nancy M Heddle
Noninfectious adverse effects of blood transfusion in the neonate.
Transfusion medicine reviews 1995;9(3):277-87.
1995: William P Sheffield; Morris A Blajchman
Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin.
FEBS letters 1995;365(2-3):189-92.
1995: Paul C Hébert; George Wells; John Marshall; Claudio Martin; M Tweeddale; Giuseppe Pagliarello; Morris A Blajchman
Transfusion requirements in critical care. A pilot study. Canadian Critical Care Trials Group.
JAMA : the journal of the American Medical Association 1995;273(18):1439-44.
1995: L Liu; L Dewar; Y Song; M Kulczycky; Morris A Blajchman; John W Fenton; M Andrew; M Delorme; J Ginsberg; K T Preissner
Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Thrombosis and haemostasis 1995;73(3):405-12.
1995: José Orlando Bordin; Morris A Blajchman
Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy.
Hematology/oncology clinics of North America 1995;9(1):205-18.
1995: Morris A Blajchman; José Orlando Bordin
The tumor growth-promoting effect of allogeneic blood transfusions.
Immunological investigations 1995;24(1-2):311-7.
1995: Morris A Blajchman
Bacterial contamination of blood products and the value of pre-transfusion testing.
Immunological investigations 1995;24(1-2):163-70.
1994: Morris A Blajchman; José Orlando Bordin
Mechanisms of transfusion-associated immunosuppression.
Current opinion in hematology 1994;1(6):457-61.
1994: H Ni; Morris A Blajchman
Understanding the polymerase chain reaction.
Transfusion medicine reviews 1994;8(4):242-52.
1994: José Orlando Bordin; Nancy M Heddle; Morris A Blajchman
Biologic effects of leukocytes present in transfused cellular blood products.
Blood 1994;84(6):1703-21.
1994: William P Sheffield; Morris A Blajchman
Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function.
Thrombosis research 1994;75(3):293-305.
1994: José Orlando Bordin; L Bardossy; Morris A Blajchman
Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion.
Blood 1994;84(1):344-8.
1994: H Moraes-Souza; José Orlando Bordin; L Bardossy; Morris A Blajchman
Efficacy of leukodepletion filters in removing T. cruzi from contaminated blood.
Revista da Sociedade Brasileira de Medicina Tropical 1994;27(3):175.
1994: S Chaing; B Clarke; S Sridhara; K Chu; P Friedman; W VanDusen; Harold R Roberts; Morris A Blajchman; Dougald M Monroe; Katherine A High
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor.
Blood 1994;83(12):3524-35.
1994: H Ni; John S Waye; William P Sheffield; Barry Eng; Morris A Blajchman
Genetic linkage studies in antithrombin-deficient kindreds using a highly polymorphic trinucleotide short tandem repeat (STR) within the human antithrombin gene.
American journal of hematology 1994;46(2):107-11.
1994: William P Sheffield; P D Schuyler; Morris A Blajchman
Molecular cloning and expression of rabbit heparin cofactor II: a plasma thrombin inhibitor highly conserved between species.
Thrombosis and haemostasis 1994;71(6):778-82.
1994: H Ni; John S Waye; Richard C Austin; D Calverley; Barry Eng; William P Sheffield; Morris A Blajchman
Characterization of a highly polymorphic trinucleotide short tandem repeat within the human antithrombin gene.
Thrombosis research 1994;74(3):303-7.
1994: P S Wells; Morris A Blajchman; P Henderson; M J Wells; C Demers; R Bourque; A McAvoy
Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study.
American journal of hematology 1994;45(4):321-4.
1994: John S Waye; Barry Eng; H Y Ni; Morris A Blajchman; G Carmody
Trinucleotide repeat polymorphism within the human antithrombin gene (AT3): allele frequency data for three population groups.
Molecular and cellular probes 1994;8(2):149-54.
1994: William P Sheffield; Morris A Blajchman
Site-directed mutagenesis of the P2 residue of human antithrombin.
FEBS letters 1994;339(1-2):147-50.
1994: Morris A Blajchman; José Orlando Bordin; L Bardossy; Nancy M Heddle
The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals.
British journal of haematology 1994;86(2):347-50.
1994: Y I Wu; William P Sheffield; Morris A Blajchman
Defining the heparin-binding domain of antithrombin.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1994;5(1):83-95.
1994: A M Ali; T E Warkentin; L Bardossy; C H Goldsmith; Morris A Blajchman
Platelet concentrates stored for 5 days in a reduced volume of plasma maintain hemostatic function and viability.
Transfusion 1994;34(1):44-7.
1994: Morris A Blajchman
An overview of the mechanism of action of antithrombin and its inherited deficiency states.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1994;5 Suppl 1():S5-11; discussion S59-64.
1994: Morris A Blajchman; A M Ali; H L Richardson
Bacterial contamination of cellular blood components.
Vox sanguinis 1994;67 Suppl 3():25-33.
1993: José Orlando Bordin; L Bardossy; Morris A Blajchman
Experimental animal model of refractoriness to donor platelets: the effect of plasma removal and the extent of white cell reduction on allogeneic alloimmunization.
Transfusion 1993;33(10):798-801.
1993: S Sridhara; B J Clarke; Morris A Blajchman
Arginine-79 in the first epidermal growth factor domain of factor VII is essential for the interaction with tissue factor.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1993;4(3):505-8.
1993: S Sridhara; B J Clarke; Frederick A Ofosu; Katherine A High; Morris A Blajchman
The direct binding of human factor VII in plasma to recombinant human tissue factor.
Thrombosis research 1993;70(4):307-16.
1993: Morris A Blajchman; L Bardossy; R Carmen; A Sastry; DP Singal
Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells.
Blood 1993;81(7):1880-2.
1993: C Demers; P Henderson; Morris A Blajchman; M J Wells; Lesley Mitchell; Marilyn Johnston; Frederick A Ofosu; F Fernandez-Rachubinski; Maureen Andrew; J Hirsh
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Thrombosis and haemostasis 1993;69(3):231-5.
1993: A B Brothers; B J Clarke; William P Sheffield; Morris A Blajchman
Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII.
Thrombosis research 1993;69(2):231-8.
1993: DP Singal; B Frame; S Joseph; Morris A Blajchman; Brian Leber
Nucleotide sequences of an antiidiotypic antibody from a transplant recipient.
Immunogenetics 1993;38(3):242.
1992: Morris A Blajchman; Richard C Austin; F Fernandez-Rachubinski; William P Sheffield
Molecular basis of inherited human antithrombin deficiency.
Blood 1992;80(9):2159-71.
1992: Frederick A Ofosu; M Levine; S Craven; L Dewar; S Shafai; Morris A Blajchman
Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent.
British journal of haematology 1992;82(2):400-5.
1992: Frederick A Ofosu; J Leclerc; F Delorme; S Craven; S Shafai; L Frewin; Morris A Blajchman
The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery.
British journal of haematology 1992;82(2):391-9.
1992: F Fernandez-Rachubinski; Richard A Rachubinski; Morris A Blajchman
Partial deletion of an antithrombin III allele in a kindred with a type 1 deficiency.
Blood 1992;80(6):1476-85.
1992: J K Wu; William P Sheffield; Morris A Blajchman
Molecular cloning and cell-free expression of mouse antithrombin III.
Thrombosis and haemostasis 1992;68(3):291-6.
1992: C Bérubé; Frederick A Ofosu; John G Kelton; Morris A Blajchman
A novel congenital haemostatic defect: combined factor VII and factor XI deficiency.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1992;3(4):357-60.
1992: C Demers; J S Ginsberg; P Henderson; Frederick A Ofosu; Jeffrey I Weitz; Morris A Blajchman
Measurement of markers of activated coagulation in antithrombin III deficient subjects.
Thrombosis and haemostasis 1992;67(5):542-4.
1992: Frederick A Ofosu; J W Fenton; J Maraganore; Morris A Blajchman; X Yang; L Smith; N Anvari; Michael R Buchanan; J Hirsh
Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.
The Biochemical journal 1992;283 ( Pt 3)():893-7.
1992: William P Sheffield; A B Brothers; M J Wells; Mark W C Hatton; B J Clarke; Morris A Blajchman
Molecular cloning and expression of rabbit antithrombin III.
Blood 1992;79(9):2330-9.
1992: C Demers; J S Ginsberg; J Hirsh; P Henderson; Morris A Blajchman
Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review.
Annals of internal medicine 1992;116(9):754-61.
1992: Morris A Blajchman; F Fernandez-Rachubinski; William P Sheffield; Richard C Austin; S Schulman
Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity.
Blood 1992;79(6):1428-34.
1992: Richard C Austin; William P Sheffield; Richard A Rachubinski; Morris A Blajchman
The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.
The Biochemical journal 1992;282 ( Pt 2)():345-51.
1992: Morris A Blajchman; L Bardossy; R A Carmen; M Goldman; Nancy M Heddle; DP Singal
An animal model of allogeneic donor platelet refractoriness: the effect of the time of leukodepletion.
Blood 1992;79(5):1371-5.
1992: B J Clarke; Frederick A Ofosu; S Sridhara; Robert D Bona; Frederick R Rickles; Morris A Blajchman
The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor.
FEBS letters 1992;298(2-3):206-10.
1992: Frederick A Ofosu; J Fareed; L M Smith; N Anvari; D Hoppensteadt; Morris A Blajchman
Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082.
European journal of biochemistry / FEBS 1992;203(1-2):121-5.
1992: F Fernandez-Rachubinski; Morris A Blajchman
A useful restriction analysis for the determination of human antithrombin III variants with mutations from Ala 382 to Ala 384.
Thrombosis research 1992;65(1):117-20.
1992: S Shirwadkar; Morris A Blajchman; B Frame; DP Singal
Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice.
Journal of cancer research and clinical oncology 1992;118(3):176-80.
1991: M Goldman; B Frame; D P Singal; Morris A Blajchman
Effect of blood transfusion on survival in a mouse bacterial peritonitis model.
Transfusion 1991;31(8):710-2.
1991: Max Chernesky; Morris A Blajchman; Santina Castriciano; J Basbaum; C Spiak; James B Mahony
Analysis of a pregnancy-screening and neonatal-immunization program for hepatitis B in Hamilton, Ontario, Canada, 1977-1988.
Journal of medical virology 1991;35(1):50-4.
1991: Morris A Blajchman
The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model.
Seminars in hematology 1991;28(3 Suppl 5):14-7.
1991: Richard C Austin; Richard A Rachubinski; Frederick A Ofosu; Morris A Blajchman
Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
Blood 1991;77(10):2185-9.
1991: J I Okwusidi; N Anvari; M Kulczycky; Morris A Blajchman; Michael R Buchanan; Frederick A Ofosu
Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
The Journal of laboratory and clinical medicine 1991;117(5):359-64.
1991: Richard C Austin; Richard A Rachubinski; Morris A Blajchman
Site-directed mutagenesis of alanine-382 of human antithrombin III.
FEBS letters 1991;280(2):254-8.
1991: DP Singal; Brian Leber; D G Harnish; B Frame; S Joseph; Morris A Blajchman
Molecular genetic basis for the antiidiotypic antibody response associated with successful renal allograft survival in humans.
Transplantation proceedings 1991;23(1 Pt 2):1059-61.
1991: B Roussel; J Dieval; J Delobel; F Fernandez-Rachubinski; Barry Eng; Richard A Rachubinski; Morris A Blajchman
Antithrombin III-Amiens: a new family with an Arg47----Cys inherited variant of antithrombin III with impaired heparin cofactor activity.
American journal of hematology 1991;36(1):25-9.
1991: M Goldman; Morris A Blajchman
Blood product-associated bacterial sepsis.
Transfusion medicine reviews 1991;5(1):73-83.
1990: X J Yang; Morris A Blajchman; S Craven; L M Smith; N Anvari; Frederick A Ofosu
Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.
The Biochemical journal 1990;272(2):399-406.
1990: Frederick A Ofosu; J Choay; N Anvari; L M Smith; Morris A Blajchman
Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
European journal of biochemistry / FEBS 1990;193(2):485-93.
1990: Richard C Austin; Richard A Rachubinski; F Fernandez-Rachubinski; Morris A Blajchman
Expression in a cell-free system of normal and variant forms of human antithrombin III. Ability to bind heparin and react with alpha-thrombin.
Blood 1990;76(8):1521-9.
1990: W J Pewarchuk; F Fernandez-Rachubinski; Richard A Rachubinski; Morris A Blajchman
Antithrombin III Sudbury: an Ala384----Pro mutation with abnormal thrombin-binding activity and thrombotic diathesis.
Thrombosis research 1990;59(4):793-7.
1990: S Shirwadkar; Morris A Blajchman; B Frame; F William Orr; DP Singal
Effect of blood transfusions on experimental pulmonary metastases in mice.
Transfusion 1990;30(2):188-90.
1990: F Fernandez-Rachubinski; Barry Eng; W W Murray; Morris A Blajchman; Richard A Rachubinski
Incorporation of 7-deaza dGTP during the amplification step in the polymerase chain reaction procedure improves subsequent DNA sequencing.
DNA sequence : the journal of DNA sequencing and mapping 1990;1(2):137-40.
1989: H E Manson; Richard C Austin; F Fernandez-Rachubinski; Richard A Rachubinski; Morris A Blajchman
The molecular pathology of inherited human antithrombin III deficiency.
Transfusion medicine reviews 1989;3(4):264-81.
1989: Morris A Blajchman; D P Singal
The role of red blood cell antigens, histocompatibility antigens, and blood transfusions on renal allograft survival.
Transfusion medicine reviews 1989;3(3):171-9.
1989: James B Mahony; K Rosenthal; Max Chernesky; Santina Castriciano; E Scheid; Morris A Blajchman; D Harnish
Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening.
Journal of clinical microbiology 1989;27(6):1234-7.
1989: A M Ali; C H Goldsmith; A T McAvoy; M A Ali; Morris A Blajchman
A prospective study evaluating the lowering of hemoglobin standards for blood donors.
Transfusion 1989;29(3):268-72.
1989: DP Singal; S Joseph; B Frame; D Ludwin; H Mervart; Morris A Blajchman
Antiidiotypic antibodies: production in vitro by EBV-transformed lymphoblastoid cell lines and immunochemical characterization of idiotypic receptors on T-cells.
Transplantation proceedings 1989;21(1 Pt 1):333-5.
1989: DP Singal; M D'Souza; B Reid; Y Kassam; W Watson Buchanan; Morris A Blajchman
Molecular analysis of the HLA-D region and the T-cell antigen receptor beta-chain genes in monozygotic twins discordant for rheumatoid arthritis.
Transplantation proceedings 1989;21(1 Pt 1):632-4.
1989: Frederick A Ofosu; J Hirsh; C T Esmon; G J Modi; L M Smith; N Anvari; Michael R Buchanan; J W Fenton; Morris A Blajchman
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa.
The Biochemical journal 1989;257(1):143-50.
1989: Morris A Blajchman; Edward Young; Frederick A Ofosu
Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits.
Annals of the New York Academy of Sciences 1989;556():245-54.
1989: Frederick A Ofosu; Michael R Buchanan; N Anvari; L M Smith; Morris A Blajchman
Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
Annals of the New York Academy of Sciences 1989;556():123-31.
1988: R Devraj-Kizuk; David H K Chui; E V Prochownik; C J Carter; Frederick A Ofosu; Morris A Blajchman
Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity.
Blood 1988;72(5):1518-23.
1988: Frederick A Ofosu; L M Smith; N Anvari; Morris A Blajchman
An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Thrombosis and haemostasis 1988;60(2):193-8.
1988: DP Singal; Morris A Blajchman; S Joseph; B Roberge; E K Smith; D Ludwin
Production in vitro of antibodies directed against alloantigen-specific recognition sites on T cells and on lymphocytotoxic HLA antibodies.
Clinical and experimental immunology 1988;72(2):222-7.
1987: Frederick A Ofosu; G J Modi; Morris A Blajchman; Michael Buchanan; E A Johnson
Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
The Biochemical journal 1987;248(3):889-96.
1987: DP Singal; S Joseph; M Ali; Morris A Blajchman; E K Smith; D Ludwin
Anti-idiotypic antibodies and suppressor cells in patients receiving pretransplant donor-specific blood transfusions.
Transplantation proceedings 1987;19(4):3399-401.
1987: DP Singal; D Ludwin; S Joseph; Morris A Blajchman; Frederick A Ofosu; S K Liao
The blood transfusion effect: characterization of T cell alloantigen-specific receptors by sera from transfused mice.
Transplantation proceedings 1987;19(1 Pt 2):1429-31.
1981: Alan Giles; H Hoogendoorn; Morris A Blajchman
The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma.
Thrombosis research 1981;21(3):255-63.
1980: H Hoogendoorn; A Cerskus; Frederick A Ofosu; Morris A Blajchman; J Hirsh
Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.
Thrombosis research 1980;20(1):77-83.
1980: Alan Giles; H Hoogendoorn; Morris A Blajchman; J Hirsh
The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits.
Thrombosis research 1980;17(3-4):555-60.
1980: Alan Giles; M Johnston; H Hoogendoorn; Morris A Blajchman; J Hirsh
The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits.
Thrombosis research 1980;17(3-4):353-66.